Colorescience, Inc. specializes in the production and sale of mineral-based cosmetics and sunscreen products. Founded in 2000 and based in Carlsbad, California, the company offers a range of treatment products aimed at addressing various skin concerns, including pigmentation, redness, dark circles, and signs of aging, as well as catering to different skin types such as sensitive, oily, and dry skin. Its product line includes UV protectors, primers, foundations, and enhancers, all designed with high-quality ingredients and formulations. Colorescience distinguishes itself in the luxury aesthetic makeup market by focusing on efficacy and ease of use. The company distributes its products through a network of licensed physicians, luxury spas, retailers, and online channels, emphasizing its commitment to reducing skin cancer and other skin conditions.
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.
Vaxxas Pty. Ltd. develops and commercializes vaccine delivery technologies. It offers Nanopatch platform that induces immune system activation by targeting vaccine to the abundant immunological cells below the surface of the skin. Vaxxas Pty. Ltd. was incorporated in 2011 and is based in Sydney, Australia with an additional office location in Cambridge, Massachusetts.
Colorescience, Inc. specializes in the production and sale of mineral-based cosmetics and sunscreen products. Founded in 2000 and based in Carlsbad, California, the company offers a range of treatment products aimed at addressing various skin concerns, including pigmentation, redness, dark circles, and signs of aging, as well as catering to different skin types such as sensitive, oily, and dry skin. Its product line includes UV protectors, primers, foundations, and enhancers, all designed with high-quality ingredients and formulations. Colorescience distinguishes itself in the luxury aesthetic makeup market by focusing on efficacy and ease of use. The company distributes its products through a network of licensed physicians, luxury spas, retailers, and online channels, emphasizing its commitment to reducing skin cancer and other skin conditions.
Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes, primarily in Europe. Founded in 1996, the company develops advanced implantable CGM products, including Eversense and Eversense XL, which monitor glucose levels for up to 90 and 180 days, respectively. Using innovative fluorescence sensing technology, these systems are designed to provide high accuracy and stability throughout their extended sensor life. The company aims to empower people with diabetes to manage their condition more effectively and confidently through its CGM solutions, which also include a smart transmitter and a mobile app. A significant portion of Senseonics' revenue is generated from markets outside the United States.
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation.
Founded in 1997, the company is headquartered in South San Francisco, California.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute tissue damaging inflammation in myocardial infarction, burns, vascular injury, and reperfusion. It develops therapeutics for treating second degree burns and prevents reperfusion injury in transplant patients. DecImmune Therapeutics, Inc. was formerly known as Natural Antibodies, Inc. and changed its name to DecImmune Therapeutics, Inc. in September 2004. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.
Cleveland HeartLab, Inc. is a specialty clinical laboratory and disease management company focused on novel biomarker technologies and the creation of proprietary diagnostic tests.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
GITR
Venture Round in 2012
GITR Inc. develops therapies to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
Private Equity Round in 2011
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Mosaic Biosciences, Inc. is a company focused on developing biomaterials for tissue engineering applications, particularly synthetic extracellular materials that facilitate natural tissue regeneration. Based in Boulder, Colorado, and incorporated in 2009, Mosaic utilizes its proprietary technology platform to create novel scaffolds with specific biophysical and biochemical properties. These scaffolds are designed for a range of medical applications, including wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. The company's innovative approach aims to significantly advance the field of regenerative medicine and support the development of effective solutions for various medical needs. Mosaic Biosciences also collaborates strategically with Catalyst Biosciences to enhance its research and development efforts.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company‟s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The company‟s lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.
Cleveland HeartLab, Inc. is a specialty clinical laboratory and disease management company focused on novel biomarker technologies and the creation of proprietary diagnostic tests.
Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics—products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.
Vaxxas Pty. Ltd. develops and commercializes vaccine delivery technologies. It offers Nanopatch platform that induces immune system activation by targeting vaccine to the abundant immunological cells below the surface of the skin. Vaxxas Pty. Ltd. was incorporated in 2011 and is based in Sydney, Australia with an additional office location in Cambridge, Massachusetts.
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Cool Energy, Inc. specializes in developing systems that harness renewable energy to produce carbon-free power. The company's primary product, the ThermoHeart® Engine, converts low-temperature waste heat into electricity, efficiently generating up to 25 kilowatts of clean power from sources such as industrial exhaust stacks and stationary power generators. This engine operates on the principles of the Stirling cycle, utilizing advanced technologies such as self-lubricating seals and high-surface-area heat exchangers to optimize performance. The ThermoHeart® Engine is particularly suited for applications in waste heat recovery, as well as in biomass and solar thermal power systems. Founded in 2006 and headquartered in Boulder, Colorado, Cool Energy aims to provide innovative energy solutions that contribute to sustainability and efficiency across various industries.
nanoMR has developed the first system for rapid isolation of rare cells from complex matrices at levels of 1 cell/mL or lower. The immunomagnetic capture system can target multiple cell types simultaneously, for example capturing bacteria and fungi from bloodstream infections, or specific cell types, such as circulating tumor, or fetal, cells, in less than 30 minutes.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition.
The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.
The company was founded in 2007 and is headquartered in Lexington, Massachusetts.
DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute tissue damaging inflammation in myocardial infarction, burns, vascular injury, and reperfusion. It develops therapeutics for treating second degree burns and prevents reperfusion injury in transplant patients. DecImmune Therapeutics, Inc. was formerly known as Natural Antibodies, Inc. and changed its name to DecImmune Therapeutics, Inc. in September 2004. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.
Anchor Therapeutics, Inc. is a biopharmaceutical company specializing in the design and development of peptide modulators for G protein-coupled receptors (GPCRs). The company focuses on creating Pepducin lipopeptide drug candidates that target the intracellular domains of GPCRs, allowing for allosteric modulation of GPCR signaling. Anchor Therapeutics aims to address various medical conditions, including cancer, inflammation, metabolic diseases, heart disease, and pain, through its innovative drug development platform. The company is engaged in pre-clinical research and offers internal programs targeting serious medical indications, such as diabetes and regenerative medicine. Originally incorporated as Ascent Therapeutics in 2006, the company rebranded to Anchor Therapeutics in 2010 and is located in Cambridge, Massachusetts.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Seahorse Bioscience provides analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. The company's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers.
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, a recombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland.
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.
Seahorse Bioscience provides analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. The company's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers.
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation.
Founded in 1997, the company is headquartered in South San Francisco, California.
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
InfaCare Pharmaceutical is a specialty pharmaceutical company focused on developing and commercializing treatments for neonatal and pediatric patients. Founded in 2005 and headquartered in Trevose, Pennsylvania, the company is advancing its lead product, Stanate, which is designed to treat infantile jaundice, also known as hyperbilirubinemia. Stanate is a heme oxygenase inhibitor administered via a single intramuscular injection, targeting the breakdown of heme and inhibiting bilirubin production in both term and preterm newborns. This innovative approach aims to reduce the necessity for common interventions such as phototherapy and exchange transfusions, thereby improving care for vulnerable infant populations.
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Their mission is to provide you with personalized, high-quality care. They are dedicated to helping you through all aspects of your neurological and surgical care. From diagnosis to management, their team is at your service, ensuring our best, for you, each and every time.
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.
MiddleBrook Pharmaceuticals is a pharmaceutical company offering anti-infective products and antibiotics.
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Advancis is a pharmaceutical company focused on developing and commercializing novel anti-infective products.
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition.
The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.
Anexon, Inc., a pharmaceutical company, develops therapeutics for cardiovascular diseases. The company is based in Cambridge, Massachusetts.
Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.
Bikam Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. Bikam's primary innovation lies in its small molecule, non-retinoid pharmacological chaperones, which target misfolded proteins within the retina. These pharmacological chaperones are designed to bind to misfolded rod opsin, a protein associated with retinitis pigmentosa, facilitating its proper trafficking to rod cell surfaces and outer segments. Through its research and development efforts, Bikam Pharmaceuticals aims to address critical unmet medical needs in the field of ophthalmology, particularly for rare genetic disorders that can lead to blindness.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Orqis Medical
Series D in 2007
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.
RedPath Integrated Pathology, LLC operates as a reference laboratory and provides support services for oncology cases. It offers PathFinderTG, a testing platform for resolving diagnoses from the original pathology specimen. The company serves pathologists, clinicians, and patients. RedPath Integrated Pathology, LLC was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation.
Founded in 1997, the company is headquartered in South San Francisco, California.
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.
PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, a recombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland.
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Orqis Medical
Series C in 2003
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.
PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, a recombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland.
Dynogen Pharmaceuticals
Series A in 2002
Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.
Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).